Malignant Female Reproductive System Neoplasm

Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,463
Recruiting: 820
Ph III recruiting: 96
Growth YoY: +6.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (740)

clinicaltrialsPublishedShowing 2,001–2,017 of 2,017 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00189579	Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer	terminated	Phase 2	45	ARCAGY/ GINECO GROUPOTHER	1	Aug 17, 2007	clinicaltrials
NCT00490711	Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer	completed	Phase 2	7	Eli Lilly and CompanyINDUSTRY	1	Jun 25, 2007	clinicaltrials